Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Epirus Biopharmaceuticals Inc (EPRS): These Two Funds Open New Positions

Epirus Biopharmaceuticals Inc (NASDAQ:EPRS) languished around the $1.00 mark for much of 2013 and the first half of 2014, until they completed their merger with Zalicus in the middle of July 2014, which included a 10:1 stock split. The results of the merger and stock split sent shares vaulting to $11.48, though they’d eventually fall under $4.00 again. On January 7 however, it jumped more than 33% following the news that the FDA had unanimously recommended approval of another biosimilar drug for sale, Sandoz’s EP2006, a biosimilar of the cancer-fighting drug Filgastrim, marketed by Amgen, Inc. (NASDAQ:AMGN) as Neupogen. The landmark ruling opened a clear path for the approval of Epirus’ own biosimilar drugs, assuming proper study results, which in the case of BOW015, they have shown.

Despite that, Epirus Biopharmaceuticals Inc (NASDAQ:EPRS) has again fallen back under $5.00, making it an attractive moderate-risk, high-reward play. The most recent analyst to comment on the stock was Leerink Swann, which initiated coverage back in October with an ‘Outperform’ rating and $12.00 price target. Given Pfizer Inc. (NYSE:PFE)’s recent purchase for $15 billion of another biosimilar maker, Hospira, Inc. (NYSE:HSP), it’s possible Epirus also becomes a takeover target, especially given its current light trading levels which have it valued at a market cap of just $113.19 million. Needless to say, any such move would likely be a coup for Epirus shareholders.

Disclosure: None

DOWNLOAD FREE REPORT: Warren Buffett's Best Stock Picks

Let Warren Buffett, George Soros, Steve Cohen, and Daniel Loeb WORK FOR YOU.

If you want to beat the low cost index funds by 19 percentage points per year, look no further than our monthly newsletter.In this free report you can find an in-depth analysis of the performance of Warren Buffett's entire historical stock picks. We uncovered Warren Buffett's Best Stock Picks and a way to for Buffett to improve his returns by more than 4 percentage points per year.

Bonus Biotech Stock Pick: You can also find a detailed bonus biotech stock pick that we expect to return more than 50% within 12 months.
Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.